Health, Medical, Research, Science

Vitamin D: Who should take it?

HEALTH

Intro: Vitamin D’s main role is in helping your body to absorb calcium from food. If you don’t get enough, the body draws calcium out of your bones

As the winter nights draw closer, many of us will be reaching for the vitamin D tablets. One of the UK’s most popular supplements, the “sunshine vitamin” is known to be essential for healthy bones, teeth, and muscles – and the NHS advises all adults to take a daily 10mcg supplement from October/November to April, when the sun’s rays are too weak for our skin to make it.

Many older people also take it year-round (as the skin’s production of it declines with age and they spend less time outdoors). More recently, research has suggested it also plays an important role in immunity and may even help to prevent dementia and cancer.

But a new study appears to raise questions about who really needs it.

Published in the British Medical Journal (BMJ), the research showed that vitamin D supplements made no meaningful difference to whether older people suffered bone fractures.

The accepted wisdom is that supplements are vital during winter months because of the low position of the sun in the sky. Susan Lanham-New, a professor of nutrition at the University of Surrey and a leading expert on vitamin D, explains: “When UV rays hit our skin, it triggers sterol 7-DHC [a precursor of vitamin D] that sits just under the skin, to commence production of an active form of the vitamin.”

In the UK, ten to 15 minutes of midday sun on bare skin in spring and summer is generally considered sufficient to manufacture our body’s recommended daily need for 10mcg. But the weaker rays in the winter months do not contain the UVB rays that our bodies need to make it, says Professor Lanham-New.

Vitamin D’s main role is in helping your body to absorb calcium from food. If you don’t get enough, the body draws calcium out of your bones. Over time, this makes them more fragile, raising the risk of fractures and osteoporosis (which affects more than three million Britons).

Although certain foods, including oily fish, eggs and fortified breakfast cereals contain modest amounts, you’re only likely to get about a third of your daily requirement from food at best.

About one in six adults in the UK is deficient in vitamin D – and the figure rises to one in three during winter months.

The NHS recommendation to take a supplement is based on the evidence for the nutrient’s crucial role in bone health and follows a 2016 recommendation by an independent committee of experts, the Scientific Advisory Committee on Nutrition (SACN).

Earlier this year, however, the recommendation was challenged as being too low by a group of UK doctors. They argued in the journal Frontiers in Endocrinology that the definition of vitamin D deficiency – a blood level of anything under 25nmol/l – should be increased to 50nmol/l, the threshold used by the World Health Organisation, the US National Academy of Medicine and the European Food Safety Authority.

The doctors cited the fact that, although uncommon, rickets – weak bones due to a lack of vitamin D – has not been wiped out, with about 480 hospital cases in year in England alone. Another argument is that people with obesity, those with darker skin (which absorbs less from the sun) and people in deprived areas who may not have sufficient quantities in their diet, were more likely to be deficient.

Vitamin D intake from food has also fallen, partly because people are eating less meat and fish.

TWO

Vitamin D also plays a critical role in immunity and in preventing cardiovascular disease, cancer, and dementia. People who are severely deficient in it are 33 per cent more likely to be hospitalised with respiratory infections, according to a recent study by the University of Surrey. The researchers analysed data from 36,000 adults and found that those with a severe vitamin D deficiency – classed as a blood concentration below 15nmol/l – were a third more likely to be admitted to hospital with infections such as flu, pneumonia and bronchitis, compared to those with levels over 75nmol/l. They concluded that taking adequate vitamin D could protect against respiratory infections.

The vitamin is also thought to play a role in heart and brain health, by regulating inflammation, blood pressure-related hormones and the function of blood vessels, which could in theory reduce artery damage and high blood pressure. Laboratory research suggests it might also slow cancer cell growth and limit damaging inflammation (by enhancing immune cell function). According to Eamon Laird, a lecturer of nutrition and health at Atlantic Technological University, Sligo, Ireland, as we get older, our immune systems become less efficient and produce inflammatory molecules that circulate more freely in the body, potentially causing damage and disease. It is thought vitamin D might help to regulate this.

A US study also found that older adults who took high doses (125mcg) of the vitamin daily scored higher on memory and cognitive tests than those who didn’t take it. These findings were reported in the journal Sleep Medicine in August.

In addition, it protects cells from “rusting” caused by unstable molecules in the body and environment, and may help immune cells to remove the sticky amyloid plaques which build up in those with dementia.

Nonetheless, these results on cognition should be treated with caution, says Paresh Malhotra, a professor of clinical neurology at Imperial College London. “This was an exploratory study: The number of people studied was low and there was no before and after comparison,” he said.

He adds that the study merely used a questionnaire “to determine who took vitamin D supplements” and did not measure the vitamin D levels in participants.

THREE

More concerning is whether the latest research that shows no meaningful improvement in bone health among older people raises questions about the key reason to take vitamin D supplements in the first place.

The BMJ study pooled results from 69 trials, involving 154,000 adults aged over 65, and found that taking vitamin D made no difference to fracture rates over the following 2.5 years.

The authors concluded that the evidence “does not support routine supplementation” to prevent fractures, and they speculated that older people may be better spending their time and money on resistance exercise and balance training, which have a proven track record in this regard.

This echoes earlier large trials, including a study published in the New England Journal of Medicine in 2019, which found that taking 50mcg of vitamin D a day did not prevent fractures in generally healthy middle-aged and older people. It also did not prevent cancer or heart disease.

A study in 2022 involving 21,000 older Australians who took a monthly vitamin D pill (1,500mcg) for up to five years found that it didn’t reduce overall deaths or cancer or cardiovascular deaths.

However, Professor Lanham-New says that these trials largely involved people who already had healthy levels of the vitamin and “there’s little evidence that giving extra vitamin D to those with adequate amounts will give extra protective benefits”.

So who should take it?

Professor Lanham-New says the recommended daily supplement of 10mcg is enough to keep most people’s blood level above 25nmol/l in the winter months.

In addition, those who spend little time outdoors, including many care home residents, and people with darker skin tones whose skin makes less vitamin D from sunlight, should all take a year-round supplement, she says.

Standard
Biotechnology, Health, Medical, Pharmaceutical industry, Science

Big pharma failing to address our greatest medical threat

GLOBAL HEALTH SECURITY

Intro: Drug-resistant infections now kill more people every year than HIV or malaria, yet only six companies remain active in antibiotic research

Writing in the last few days, Professor Lord Darzi, FRS, said that big pharma is failing to tackle our greatest medical threat.

The world-renowned and eminent surgeon says that every caesarean section, joint replacement, and round of chemotherapy depends on antibiotics. In medicine as in war, a successful attack needs a solid defence. Antibiotics are not medicine’s glamourous front line – they are its foundations. And those foundations are crumbling.

Citing that drug-resistant infections now kill 1.27 million people every year, by 2050 the toll could reach eight million. The current mortality rate is more than HIV or malaria. The World Health Organisation (WHO) has warned that one in six bacterial infections is already resistant to standard treatment.

Yet this growing threat has been neglected by the very industry that has the capacity and resources to confront it. The major pharmaceutical companies walked away from antibiotics when they stopped generating lucrative returns. In the 1980s there were 18 companies involved in antibiotic research. By 2020 the number had fallen to six. The rest have pivoted to focus on expensive but highly remunerative medicines to beat cancer and long-term conditions such as obesity.

The ways in which these new medicines attack disease is indeed transformative, but they do not save lives all by themselves. Patients undergoing treatment are at higher risk of infection, but without effective antibiotics, the surgeon cannot operate safely, the oncologist cannot deliver chemotherapy, and the transplant physician cannot suppress rejection.

It is strategically incoherent to innovate relentlessly in attack while underinvesting in defence. The defensive arsenal is not optional infrastructure. It is foundational.

Between 2011 and 2020, US venture capital invested just $1.6bn in antimicrobials, compared with $26.5bn in oncology. The antimicrobial pipeline has declined by 35 per cent since 2021, from 92 to 60 projects, according to the 2026 AMR Benchmark report by the Access to Medicine Foundation, last month. Half are led by GlaxoSmithKline (GSK), which is carrying a disproportionate share of the large-company burden.

There are now only 3,000 active antimicrobial resistance (AMR) researchers worldwide, against 46,000 in oncology. When antibiotic programmes close, 90 per cent of researchers leave the field entirely. The talent and expertise needed for these medicines is collapsing alongside the drug pipeline.

This weakness puts at risk the pharmaceutical industry’s own growth. In 2024, global oncology revenues exceeded $200bn and R&D investment surpassed $40bn. Yet one-third of cancer patients develop bacterial infections during treatment, and up to half of these are now resistant – causing delays, dose changes, and poorer outcomes.

Developing new antibiotics is especially challenging. Most drugs succeed commercially by reaching as many eligible patients as possible. But for antibiotics, good stewardship means reserving novel agents for resistant infections – precisely the behaviour that collapses commercial returns.

In 2020, a consortium of more than 20 major pharmaceutical companies committed around $1bn to bridge the “valley of death” between discovery and profitability by creating the AMR Action Fund. The fund’s ambition was to deliver two to four new antibiotics by 2030. To date, it has delivered one – pivmecillinam, for urinary tract infections.

Bold initiatives such as this $1bn scheme look impressive. But there is a danger of their becoming “guilt capital” – spending that looks responsible but does not change the underlying economics. Without genuine pull incentives, and without adequate investment in diagnostics, stewardship, and surveillance alongside drugs, the spending risks being perceived as reputational insurance rather than strategic investment.

Most tellingly, the fund itself acknowledges it “struggled to find investment opportunities in clinical development exactly because the pipeline is insufficient”. When a $1bn fund cannot find enough assets worth backing, the problem is not capital. It is upstream failure to generate candidates and downstream failure to create a market that rewards success.

The conclusion is quite simple. We need a new approach.

First, build a sustainable pipeline through modern discovery – including AI-enabled research that must prove itself with real-world data – and implement payment models that reward access rather than volume. The UK’s subscription-style scheme is now being expanded. Similar approaches in other countries could create a viable global market.

Second, reduce misuse through transformative diagnostics. Rapid pathogen identification and resistance profiling at point-of-care would cut inappropriate prescribing – the single largest driver of resistance – and protect new drugs from the fate of their predecessors. A deadline should be called: no antibiotic prescription without a diagnosis by 2030.

Third, strengthen stewardship, surveillance, and access so that new antibiotics are protected, monitored, and reach patients appropriately anywhere in the world – particularly in low-income and middle-income countries where the burden of resistance is heaviest.

In 2028, we will mark the centenary of Alexander Fleming’s discovery of penicillin at St Mary’s Hospital in London – a moment that launched the antibiotic era and transformed human health. The centenary should be a moment of celebration. It risks becoming a memorial if action is not taken.

Standard
Health, Mental Health, Psychology, Wellbeing

Gratitude: Is it understood properly enough?

HEALTH & WELLBEING

THE word “gratitude” is ubiquitous and everywhere these days. On mental health leaflets and in magazine columns, it is also emblazoned on mugs and seen often on motivational posters. All this is the result of more than two decades’ research in positive psychology which has found that having a “gratitude practice” – such as jotting down three to five things you are thankful for most days – brings a host of psychological and physical benefits.

Most of us will not want to seem, well, ungrateful. Even amongst sceptics, it is likely that they too would have been persuaded to take up the gratitude habit. When we remember to do it, we will feel better: more cheerful and connected, inclined to see the good already present in our lives. Counting your blessings, whether that’s noticing a beautiful sunset or remembering how your neighbour went out of their way to help you earlier, is free and attractively simple. But there underlies the problem. In our eagerness to embrace gratitude as a cure-all, have we lost sight of its complexity and its edge?

In positive psychology, gratitude is generally defined as a wholly good thing, a spontaneous feeling of joyful appreciation. But back in 1923, the Harvard psychologist William McDougall believed gratitude – especially when directed towards another person, rather than an experience in the more abstract way of, say, being “grateful to be alive” – was more difficult and complex to understand. Of course, there was awe for the generosity of the human spirit, and tender feelings towards the person who had given up their time to help. But there were also quiet feelings of envy or embarrassment, a sense of the “superior power” of the helper and even what McDougall called “negative self-feeling” (which today we’d call “low self-esteem”). The Japanese expression arigata-meiwaku (literally: “annoying thanks”) gets to the heart of what he meant. Arigata-meiwaku is the feeling you have when someone insists on performing a favour for you, even though you don’t want them to, yet convention dictates you must be grateful anyway. There’s a reason all this feels so annoying: being grateful throws off the balance of power and increases feelings of obligation. There’s your benefactor at the top, bathed in a sunshine glow of generosity. And there’s you, at the bottom, doffing your cap.

It might seem mean-spirited to focus on how being thankful can also obligate, diminish, or even confuse us. But as #feelingblessed becomes a performative norm, these aspects of gratitude are even more important to understand, particularly for the role they play in how hierarchical structures are reinforced in our world. A bleak tale about compulsory gratitude is that of the 13-year-old orphan Eyo Ekpenyon Eyo II. In 1893, he travelled from his home in British-occupied west Africa to take up a scholarship in a missionary school in Colwyn Bay, Wales. Less than six months after arriving, Eyo wrote to his patron, expressing thanks but begging to return home. The cold weather had made him poorly, and he feared for his life. It was a reasonable worry since three west African pupils had already died at Colwyn Bay.

Some time later Eyo did secure a passage home, but not before the British press got hold of the story. In a vicious outpouring of anger, they called him “spoilt”, “ungrateful”, and a “little prince”; their language soaked in colonial assumptions about who ought to feel grateful to whom. Not much has changed since. In The Ungrateful Refugee the author Dina Nayeri describes how, as a child refugee from Iran, she was expected to feel “so lucky, so humbled” to be in the United States. Only later did she understand how this “politics of gratitude” had subtly worked to transform her human right to refuge into a gift, one that had to be repaid by staying submissive and uncomplaining, being a “good immigrant” who stayed firmly in her lane.

This connection between power and the demand for gratitude reaches into many parts of life. When people in high-power positions are made to feel insecure, such as by having their failings and shortcomings pointed out, they commonly berate those who they perceive as inferior to them for being ungrateful. Consider the recent incident in the White House when Donald Trump and JD Vance took Volodymyr Zelensky to task for failing to show sufficient gratitude earlier this year.

These costs are part of what psychologists now call the “dark side” of gratitude. One common objection to the gratitude movement is that it risks “toxic positivity”, encouraging people to ignore and repress more painful feelings. But feeling thankful can lead to other dangers, too. People are more likely to transgress moral codes on behalf of someone else if they feel grateful to them. Members of historically marginalised groups, including women and LGBTQ+ people, are less likely to complain about unfair treatment if they are reminded first how lucky they are compared with the past. And, as studies with women in abusive relationships show, when people have been gaslit into believing they cannot survive without an abuser, gratitude makes them feel obliged to stay. Is it apt to ask, then, whether all those motivational posters should come with caveats and health warnings?

Given these arguments there is a lot to think about while trying to jot down three things you feel grateful for so you can retire peacefully at night.

Yet, the lessons of the latest research remind us that, like all emotions, feeling grateful is neither wholly good nor wholly bad. Too little, and we risk being entitled or rude, alienating those who try to help us. Too much, and we may leave ourselves open to exploitation by amplifying the power someone holds over us. Context, as always, is necessary and should always be relative.  

There are strategies that help mitigate the risk. Focusing on circumstances rather than individuals (broadly, feeling grateful for or that, rather than grateful to) can side-step the issue of power. And if you notice someone – a boss, parent, friend, or partner – expecting more gratitude than you want to give, you might ask yourself why. What might seem like ungrateful behaviour in our hierarchical world may really be an act of self-preservation, even one of political defiance.

And sometimes gratitude does need to have an expiration date. For all we may feel thankful, sometimes we have to release ourselves from the burden and move on with our lives. Gratitude is important. But so is paying attention to its limits.

Standard